Company Overview
Rockwell Medical, Inc. operates within the healthcare sector, specifically focusing on the drug manufacturing industry for specialty and generic pharmaceuticals, where it develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company's product portfolio includes specialized concentrates such as citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, and dri-. As a publicly traded entity with the ticker symbol RMTI, the firm functions as a niche player in the broader pharmaceutical landscape rather than a massive conglomerate. The company's total market capitalization stands at $34.29M, while its trailing twelve-month revenue is reported at $69.26M, and the specific count of employees is listed as N/A in available data. These valuation and revenue metrics indicate that Rockwell Medical, Inc. operates on a small-cap scale, suggesting a limited market footprint compared to large-cap pharmaceutical peers and positioning it as a micro-cap stock with higher relative risk and lower liquidity profiles. The absence of disclosed employee data further limits the ability to gauge operational scale relative to revenue, but the revenue figure confirms active commercialization efforts within the hemodialysis supply chain.
Financial Health
The company reported a trailing twelve-month revenue of $69.26M, yet it posted a net income of $-5,314,000 and an EBITDA of $-2,496,334, revealing a significant gap between top-line generation and bottom-line profitability that points to substantial operating expenses or non-operating charges. While the specific free cash flow figure is listed as N/A, the disparity between the negative net income and negative EBITDA suggests that the company is burning capital, which limits its financial flexibility for organic expansion without external financing. The gross margin stands at 16.9%, indicating that after cost of goods sold, the company retains a modest portion of revenue, while the operating margin is negative at -2.2% and the profit margin is significantly lower at -7.7%, reflecting high overhead costs relative to sales. The firm holds $23.71M in cash against $13.12M in debt, resulting in a debt-to-equity ratio of 35.45, which suggests a balance sheet that is currently leveraged but retains a net cash position, though the negative earnings erode equity over time. A current ratio is listed as N/A, preventing a direct assessment of short-term liquidity based on standard current assets to current liabilities ratios, though the net cash position provides a buffer against short-term obligations. Return on Equity is reported at -15.3%, while return on assets is N/A, indicating that management is currently destroying shareholder value rather than generating returns on the capital base.
Valuation Assessment
Rockwell Medical, Inc. displays a trailing P/E ratio of N/A due to its negative earnings, whereas the forward P/E is 12.43, implying that the market expects a significant earnings turnaround to justify current pricing or that valuation models are relying on projected future profitability rather than historical performance. The price-to-book ratio is 0.93, suggesting that the market values the company slightly below its book value, which often indicates skepticism regarding the quality of assets or the company's ability to generate returns on that capital in the near term. Alternative valuation metrics include a price-to-sales ratio of 0.50 and an EV/EBITDA of -9.50, which highlights that the stock is trading at a deep discount relative to sales but carries a negative enterprise value multiple due to its negative EBITDA. The stock has traded between a 52-week high of $2.10 and a 52-week low of $0.78, and without a specific current price provided in the facts, the valuation is strictly contextualized by these historical trading ranges which define the volatility envelope. The beta is listed as N/A, meaning that the stock's specific volatility relative to the broader market cannot be quantified from the available data, though the wide spread between the high and low suggests inherent price instability.
Growth & Income
Revenue growth year-over-year is negative at -25.6%, while earnings growth is N/A, indicating that the company is contracting its top line and failing to generate profitable growth, which implies a challenging operational environment or loss of market share. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings, though currently negative, to fund operations rather than distributing income to shareholders. The absence of a dividend yield and the negative earnings growth profile suggest that Rockwell Medical, Inc. is prioritizing capital preservation or turnaround efforts over income generation for investors. The overall growth and income profile is characterized by declining revenue, negative profitability, and no dividend distribution, presenting a high-risk, non-income-generating equity position for investors seeking stability or cash flow.